Flagship · Bulletin

Macro rationale

Neutral, unchanged. The macro digest keeps the extension escalator active (QQQ +9.29% above its 200d), which is the only thing authorizing cash above the 15% base-band top; I am using that headroom but curing the carried 25.60% back under the 25% escalated ceiling. The Aug-14 stagflation frame is intact and dated: July NFP -23k with -103k revisions, Fed pinned at 3.63% with three hike-dissents and no forward guidance, headline CPI 3.4% with energy +14.7% YoY, 10y real yield 2.35% genuinely restrictive, and HY OAS at 2.75% in its richest decile — macro fragility priced as if it were absent. Warsh at Jackson Hole on Aug 28 is a live, dated policy tail six days out; VIX at 16 says the tape is not paying for it. But the internals do not say risk-off either: 63% of sectors above their 50d, equal-weight +0.87pp vs SPY over 1m, and rotation led by XBI +5.14pp / XLV +4.43pp / XLE +3.44pp against XLI -4.66pp and XLU -11.13pp. That is defensive-and-broadening leadership, not distribution. The five nearest historical analogs are all neutral-regime, VIX 15-17, HY OAS ~3 tapes where we traded nothing and the book still ran +5.46% / +6.66% vs SPY +2.85% / +2.55% over the following 30d. That is a direct argument for holding the core and letting the compounders work. Nothing in this week's flow touched a funder. The SCCO trigger (+8.97%) is copper repricing on the ~320kt 2026 deficit and AI-datacenter draw — my thesis confirming, not breaking. NEM's move is the Aug-19 Treasury long-bond buyback expansion compressing long yields, which is exactly the stagflation-hedge mechanism the §5.3 slot exists to capture. GEV's flag is a 34x multiple, not a backlog cancellation; the $176B book still runs to 2031. LLY, VRTX and ARGX all got competitor-failure or approval news that widens their moats. So: regime holds, cash comes back inside the ceiling, and the only real work is restoring the §2 position count.

Thesis

Two tickets, both floor restoration; every other name is copied verbatim at entry weight, delta 0. The book is 14 vs the §2 16-name floor and opens are scope-locked to [BEAM, NVS]. NVS clears on its own merits and I am changing its basis: the desk vetted it as technical_rebound, but at 7.2% above its 200d with RSI 57 that framing is wrong and the red team said so. The honest lane is durable_value — a top-5 global pharma at ~14x forward earnings with ~40% core operating margin, a live multi-billion buyback, and a management record that spun Alcon and Sandoz rather than empire-building. The red team's kill case is that Pluvicto (~$1B, <2% of revenue) cannot carry a $52B-revenue company facing the 2027-28 Cosentyx/Kisqali cliff. Agreed — which is why Pluvicto is not my thesis and not in my unwind condition. I am buying diversified in-market cash flow (Kisqali, Scemblix, Leqvio, Fabhalta) at a value multiple, with Swiss-ADR non-US ballast, in the pillar the brief calls underweight precisely because rate-sensitive clinical-stage biotech is the wrong expression — commercial, cash-generative pharma is the right one. 3.0% starter with named scale-in and kill. BEAM is the harder call and I size it accordingly: 1.5% growth-starter, an option not an anchor. It is pre-revenue at $2.7B with $350-400M burn and the red team's 0.60 p_fail is fair. What I am underwriting is BEAM-302 — human proof of in-vivo single-base correction in AATD, funded to data — with Lilly's ~$1.3B Verve acquisiti

Reflection

Zero funder breaks again. SCCO +9% is the copper deficit confirming, NEM is the Treasury buyback compressing real yields — both hedges doing their job. Only work: refill the §2 floor.

I keep being fired on price and 13F sentiment; this week the trigger names were my two hedges DOING WHAT HEDGES DO, and the briefer's instinct on both was 'trim the drift.' I want to name that pattern: drift-driven trim advice on a working hedge is the exact opposite of the §5.3 slot's purpose. Second, I changed NVS's basis from technical_rebound to durable_value because the vetted framing was factually wrong (7.2% above 200d, RSI 57 is not oversold) — the red team caught it before I did, which is a point for reading their pre-brief as evidence not obstacle. Third, foundation is still empty; s

Positions (16)

• MUMicron Technologycompute

  hold3.86%87
  flow acceleratingconf

  Funder

  Only US-domiciled leading-edge DRAM/HBM franchise: 84.6% gross margin, FCF positive, and genuine supply discipline after two decades of cycle abuse — a three-player HBM oligopoly with real scarcity rents. Named flow: 16 Strategic Customer Agreements worth ~$100B of contracted HBM, 2026 supply fully pre-sold, HBM pricing +246% YoY in 2025, capex lifted to $20B. Druckenmiller exited on valuation the

  Unwind

  Erosion of the 16-SCA contract book; HBM oversupply as new capacity lands late-2026; a named hyperscaler capex cut; or CXMT Beijing capacity landing at scale in commodity DRAM and breaking pricing. A famous-manager exit after a 231-300% run is a valuation opinion, not a contract cancellation, and is not in this list.

  Catalyst

  FQ4 results late September 2026 — HBM4 qualification status and whether the FY27 SCA book extends beyond the ~$100B already contracted.

  Scenarios · 12mo targets

  $1,150.00 base

  $1,450.00 bull — HBM4 qualifies at Rubin volumes and Micron holds 22-23% share; 2027 supply pre-sells at higher prices, lifting through-cycle margins above the last peak.

  $620.00 bear — Late-2026 capacity additions plus CXMT commodity DRAM break pricing; SCA volumes get renegotiated and the memory cycle rolls the way it always has.

• TSMTaiwan Semiconductor Manufacturingcompute

  hold5.83%86
  flow acceleratingconf

  Funder

  World-leading foundry with an effective monopoly at <=3nm — every meaningful AI accelerator routes through it. >50% gross margin, prodigious FCF, famously disciplined capex, ~73% foundry and ~90% advanced-node share. Named flow: 2026 capex guided $60-64B, CoWoS booked out through end-2026 (75-80 KWPM scaling to 115-140), CHIPS $6.6B Arizona disbursement, and ~$600B of AMZN/GOOGL/MSFT datacenter co

  Unwind

  Gross margin sustained <50% for two consecutive quarters; a rival closing the leading-edge yield gap; a Taiwan-strait event Arizona capacity cannot offset; or foundry capex guidance cut outright rather than reallocated.

  Catalyst

  Q3 results mid-October 2026 plus monthly revenue prints — first read on 2027 capex and A16/N2 ramp allocation.

  Scenarios · 12mo targets

  $500.00 base

  $620.00 bull — N2 ramps at premium pricing while CoWoS constraint keeps allocation power with TSMC; the $4T-by-2028 market-cap path the sell side is now modelling gets pulled forward.

  $320.00 bear — An AI digestion quarter lands while Arizona/Japan fab costs dilute margin below 50%, and a Taiwan geopolitical scare compresses the multiple regardless of earnings.

• NVDANVIDIAcompute

  hold3.61%74
  flow steadyconf

  Funder

  AI-accelerator franchise with the CUDA software moat — ~74.9% gross margin, fortress balance sheet, and developer lock-in no ASIC rival has replicated in a decade. Named flow: ~$725B of 2026 hyperscaler capex anchored on Blackwell/Rubin (MSFT, AMZN, GOOGL, META), the Stargate JV, and Anthropic at a ~$65B revenue run-rate. Loeb exited and Coleman trimmed on profit-taking while Druckenmiller accumul

  Unwind

  Data-center revenue YoY <20% for two consecutive quarters; hyperscaler in-sourcing plus AMD/Cerebras wins pushing competitor share toward the 25% TAM line; a compute export-control tightening that removes a named market; or gross margin breaking below 65%.

  Catalyst

  Q2 FY2027 results late August 2026 — data-center growth rate, Rubin ramp timing, and any quantification of custom-ASIC share loss.

  Scenarios · 12mo targets

  $260.00 base

  $330.00 bull — Rubin ramps on schedule into an unbroken $725B capex line and inference demand (Anthropic +600% YoY) keeps accelerator scarcity intact through 2027.

  $150.00 bear — Hyperscaler in-sourcing plus AMD/Cerebras take visible share, data-center growth decelerates below 20%, and the market re-rates a cyclical away from a monopoly multiple.

• ASMLASML Holdingcompute

  hold2.96%61
  flow steadyconf

  Funder

  EUV / High-NA monopoly — the single most irreplaceable tool in advanced semis, no commercial-scale alternative at 2nm, multi-year backlog, ~50% gross margin, plus an installed-base service annuity that survives order troughs. Named flow: 60 low-NA EUV units planned for 2026 (+25% units), $36-40B revenue guided, High-NA moving into high-volume manufacturing, and the TSMC/Samsung/Intel 2026-27 order

  Unwind

  Book-to-bill <0.7 for three consecutive quarters; a Dutch/US export-control tightening removing a material share of the orderbook; or a credible non-EUV patterning path at 2nm. Score drift from 85 to 61 with no bookings break is drift, not a trigger.

  Catalyst

  Q3 results mid-October 2026 — bookings/book-to-bill and the first hard 2027 EUV unit guide.

  Scenarios · 12mo targets

  $2,050.00 base

  $2,500.00 bull — 2027 EUV unit guidance steps up again on TSMC N2/A16 and Samsung recovery; High-NA converts from pilot to repeat orders and the service annuity compounds.

  $1,250.00 bear — A digestion year in litho orders plus a further Dutch export-control tightening on China service revenue drives book-to-bill below 0.7 for three quarters.

• AVGOBroadcomcompute

  hold2.92%63
  flow steadyconf

  Funder

  Custom-silicon ASIC leader (~70% share) plus the VMware infrastructure-software lock-in — 69.5% gross margin, huge FCF, $7B+ annual buyback, serial dividend grower, and one of the best capital-allocation records in semis under Tan. Named flow: the GOOG TPU multi-generation program, META MTIA, and Anthropic ASIC contracts, with AI bookings above $30B. Loeb sold 50k shares and Druckenmiller exited —

  Unwind

  AI custom-chip revenue stalling below a ~$25B annual run-rate; full hyperscaler in-sourcing displacing the ASIC design franchise; VMware renewal churn breaking the software annuity; or the buyback being suspended to fund an acquisition.

  Catalyst

  FQ3 results early September 2026 — AI semiconductor revenue run-rate and whether a fourth named ASIC customer is disclosed.

  Scenarios · 12mo targets

  $440.00 base

  $540.00 bull — A fourth hyperscaler ASIC program is confirmed and VMware renewals hold price; AI revenue clears a $30B+ run-rate and the software annuity re-rates the whole company.

  $265.00 bear — Google or Meta pulls design work in-house, AI silicon stalls near $25B, and VMware renewal churn exposes how much of the multiple rests on that annuity.

• ANETArista Networkscompute

  hold2.60%65
  flow acceleratingconf

  Funder

  Durable hyperscaler-networking franchise and a consistent share-gainer since 2004 — 62.9% gross margin, net cash with no debt, and the single-image EOS software moat that keeps switching costs high; Ullal's capital discipline is the record. Named flow: first $3B quarter (Q2 revenue $3.04B, +37.7% YoY) with FY guidance raised to $12.6B (+40%), funded directly by named Microsoft and Meta AI-cluster

  Unwind

  Microsoft+Meta combined concentration >50% with revenue decelerating; Spectrum-X or whitebox displacing EOS in a NAMED hyperscaler footprint; or gross margin breaking below 60% as AI-cluster mix dilutes campus economics.

  Catalyst

  Q3 results early November 2026 — hyperscaler concentration disclosure and any quantification of Spectrum-X displacement.

  Scenarios · 12mo targets

  $225.00 base

  $280.00 bull — EOS holds its footprint through the 800G upgrade cycle and campus/enterprise diversifies the customer base while AI-cluster revenue compounds at 40%.

  $130.00 bear — Nvidia Spectrum-X (already $14.8B, +199% YoY) displaces Arista in a named hyperscaler and gross margin breaks 60% as the mix shifts.

• GEVGE Vernovaenergy

  hold5.71%61
  flow acceleratingconf

  Funder

  Gas-turbine and grid franchise with genuine pricing power — heavy-duty turbines effectively sold out through 2030 and 10-20% price realization on new orders, an installed-base service annuity, and post-spin balance-sheet cleanup. Named flow: record ~$176B backlog running to 2031, Morgan Stanley's 38GW power-gap work, DOE's ~100GW-by-2030 grid need with datacenters roughly half of it, and Norway GP

  Unwind

  Gas-turbine backlog cancellation or a named hyperscaler power-capex cut; wind-segment losses widening enough to consume gas-segment profit; or EV/EBITDA breaching 25x while orders decelerate. A 34x forward multiple on a growing $176B backlog is a valuation opinion, not a backlog break.

  Catalyst

  Q3 results late October 2026 — gas orders and pricing detail, plus confirmation that wind-segment losses are contained.

  Scenarios · 12mo targets

  $1,120.00 base

  $1,400.00 bull — Backlog pushes past $200B on datacenter and grid orders, wind losses turn to breakeven, and services margin expansion converts the book into visible FCF through 2031.

  $660.00 bear — A hyperscaler power-capex pause plus widening offshore-wind charges hits earnings while a 34x multiple offers no cushion; orders slip and the spinoff re-rating unwinds.

• SCCOSouthern Copperenergy

  hold9.63%67
  flow acceleratingconf

  Funder

  Tail-risk hedge slot (§5.3): lowest-cost major copper producer with the industry's largest reserve base, 67.6% gross margin, FCF positive with a large dividend, and Grupo Mexico control enforcing capital discipline through the cycle. Named flow: ~320kt 2026 copper supply deficit, record Q1 net income $1.58B, AI datacenters drawing up to 50kt of copper per facility, and BHP flagging copper overtaki

  Unwind

  Copper price collapse breaking the deficit thesis; Tia Maria / Los Chancas permitting reversal; a dividend cut signalling balance-sheet stress; or a Peruvian/Mexican fiscal or nationalization shock. RSI 69 after a +8.97% day is price, not a thesis event.

  Catalyst

  Q3 results late October 2026 plus Tia Maria construction milestones; copper term pricing into 2027 contract season.

  Scenarios · 12mo targets

  $245.00 base

  $300.00 bull — The 2026 deficit widens as electrification and datacenter copper draw compound while no new tier-1 supply lands; Tia Maria adds volume into a record price deck.

  $155.00 bear — A China demand air-pocket collapses copper back toward marginal cost, or Peruvian permitting/community action stalls Tia Maria and Los Chancas again.

• NEMNewmont Corporationenergy

  hold6.35%84
  flow acceleratingconf

  Funder

  Tail-risk equity hedge (§5.3): largest gold producer with tier-1 long-life assets, strong post-Newcrest FCF and dividend, and visibly improving cost discipline after the divestiture program. Named flow: continued central-bank gold accumulation plus the Aug-19 Treasury long-bond buyback expansion compressing long yields (+7.9% single-day) — exactly the stagflation-hedge mechanism this slot exists t

  Unwind

  Cost overruns or mine disappointments breaking FCF and the dividend; durable disinflation plus a real-rate surge removing the stagflation-hedge rationale; or a value-destroying acquisition undoing the post-Newcrest portfolio discipline. RSI 76 is the hedge working, not a reason to sell it.

  Catalyst

  Q3 results late October 2026 (AISC and FCF post-settlement); Warsh at Jackson Hole Aug 28 sets the real-yield path this position is levered to.

  Scenarios · 12mo targets

  $150.00 base

  $190.00 bull — Warsh signals tolerance for above-target inflation while labor keeps cracking; real yields fall and central-bank buying continues into a supply-constrained gold market.

  $95.00 bear — Core CPI breaks below 2.2% for two prints, the Fed regains credibility, real yields hold 2.35%+ and gold de-rates while AISC inflation eats the FCF.

• KTOSKratos Defensedefense

  hold11.41%64
  flow steadyconf

  Funder

  Scarce non-prime supplier of attritable airframes (XQ-58A Valkyrie), hypersonics and turbine engines, with a decade of embedded program positions the primes cannot easily displace and vertical propulsion integration few peers own. Named flow: DoD MACH-TB 2.0 $1.45B IDIQ, hypersonics revenue doubling toward ~$400M with $700M potential by 2027, the $50M test facility completed ahead of schedule, and

  Unwind

  Backlog or contract cancellations; margin failing to inflect through the drone ramp with FCF staying negative; a DoD unmanned-systems funding cut; or an FY2027 appropriation that funds the primes' exquisite platforms at the expense of attritable programs.

  Catalyst

  Q3 results early November 2026 (revenue scale and margin inflection) and the FY27 appropriations / continuing-resolution outcome by Dec 4.

  Scenarios · 12mo targets

  $70.00 base

  $92.00 bull — Hypersonics clears $700M and Valkyrie converts to a program of record; the drone ramp finally inflects margin and FCF turns positive, validating the 18.5% growth rate.

  $38.00 bear — A December CR funds at prior-year levels, delaying new starts; FCF stays negative through the ramp and a 95x forward multiple compresses hard on a single guidance miss.

• HEIHEICOdefense

  hold10.23%68
  flow steadyconf

  Funder

  Defense/aero aftermarket compounder and a textbook 20-30 year franchise — the Mendelson family has owned and run it since 1957, compounding FCF at 20%+ through disciplined serial acquisition, protected by FAA PMA-approval switching costs on parts airlines cannot easily re-qualify. Named flow: record Q2 net income +49% YoY, sales $1.375B (+25%), ETG operating income +56%; NDAA mandatory funding plu

  Unwind

  Organic growth decelerating below 6% WITH margin compression; a value-destroying large acquisition breaking the tuck-in serial-acquirer discipline; or forward P/E sustained above 50x while growth decelerates. Today growth is accelerating, so the valuation screen alone does not fire.

  Catalyst

  FQ4 results in December 2026 — organic growth split versus acquired, and the FY27 acquisition pipeline commentary.

  Scenarios · 12mo targets

  $415.00 base

  $500.00 bull — FSG and ETG keep compounding above 20% as the MRO cycle runs and the family deploys $1B+/yr into accretive tuck-ins at unchanged discipline.

  $260.00 bear — Organic growth decelerates below 6% while a 54x forward multiple stays priced for perfection; one guidance cut triggers both the growth and valuation screens together.

• LLYEli Lillybiology

  hold3.81%74
  flow acceleratingconf

  Funder

  Premier pharma compounder — the tirzepatide franchise (~60% US share; Q2 Mounjaro $9.9B, Zepbound $4.9B) on 85.8% gross margin, plus a manufacturing moat from the $27B capacity build that rivals cannot replicate on any near timeframe. Named flow: Foundayo took Europe's first oral GLP-1 weight-loss approval (UK, Aug 14) with no food restrictions versus Wegovy, and retatrutide Phase 3 showed 28.7% w

  Unwind

  Tirzepatide US script share falling >5pts to Novo over two quarters; retatrutide Phase 3 disappointing on safety or durability; or IRA/MFP negotiation reaching the incretin class on terms that break the margin structure.

  Catalyst

  Q3 results late October 2026 — orforglipron launch metrics and NVO comparative script share; further retatrutide Phase 3 readouts.

  Scenarios · 12mo targets

  $1,500.00 base

  $1,850.00 bull — Oral orforglipron unlocks the primary-care and ex-US TAM Novo cannot serve at scale, and retatrutide extends the franchise a second decade at 85%+ gross margin.

  $950.00 bear — CagriSema and Ozempic tablets take visible US script share, manufacturing capacity outruns demand, and IRA price negotiation reaches the incretin class.

• VRTXVertex Pharmaceuticalsbiology

  hold3.17%82
  flow steadyconf

  Funder

  Durable biology compounder: the cystic-fibrosis monopoly (Trikafta/Alyftrek) is a self-funding cash engine on 85.3% gross margin with no meaningful competition and a fortress net-cash balance sheet, with exclusivity into the late 2030s. Named flow: Sionna's CF candidate failed in August — a competitor failure that widens the moat and extends addressable reach toward 95% of CF patients; Journavx no

  Unwind

  The CF franchise eroding faster than non-CF revenue can replace it; the Crinetics integration destroying value or pushing forward P/E toward the 30x invalidation line; or Journavx failing to gain formulary access after launch.

  Catalyst

  Q3 results late October 2026 — Journavx script trajectory, Alyftrek conversion rate, and Crinetics close/integration detail.

  Scenarios · 12mo targets

  $640.00 base

  $780.00 bull — Journavx converts a meaningful slice of the acute-pain market, Casgevy reimbursement broadens, and Crinetics adds a second self-funded franchise on CF cash flow.

  $430.00 bear — Journavx launch stalls on formulary access, Crinetics proves an expensive diversification, and the market prices Vertex as a single-asset CF company again.

• ARGXargenxbiology

  hold3.11%70
  flow acceleratingconf

  Funder

  argenx — the Vyvgart/Vyvgart Hytrulo (efgartigimod) FcRn autoimmune franchise: first-mover platform with a decade of indication runway, commercial-stage, high-margin and net cash, so it does not depend on capital markets in a 2.35% real-yield world. Named flow: Sanofi's CIDP trial failure removes the nearest challenger, positive efgartigimod data in myositis and Sjogren's, the Forte Biosciences te

  Unwind

  Vyvgart revenue growth stalling; a pipeline indication failure in myositis or Sjogren's; a competitor FcRn entrant taking measurable share; or the Forte deal turning into an integration drain rather than a bolt-on.

  Catalyst

  Forte tender expiry Aug 26 2026; Q3 results late October — Hytrulo prefilled-syringe conversion and CIDP launch trajectory.

  Scenarios · 12mo targets

  $1,230.00 base

  $1,500.00 bull — Hytrulo self-injection drives CIDP and gMG penetration while myositis and Sjogren's convert into approvals; FcRn becomes a multi-indication platform with no credible rival.

  $780.00 bear — A pipeline indication misses, Johnson/Immunovant FcRn entrants take share, and a name that already ran to RSI 74 de-rates on decelerating Vyvgart growth.

• NVSNovartis AGbiology

  open2.46%+3.00pp51
  flow steadyconf

  Funder

  Top-5 global pharma with genuinely diversified in-market cash flow — Kisqali, Scemblix, Leqvio, Fabhalta, Cosentyx — on ~40% core operating margin and strong FCF, run by a management team whose allocation record is subtraction rather than empire-building (Alcon spun, Sandoz spun, portfolio pruned to pure innovative medicines). Named flow: a multi-billion buyback authorization running at pace, plus

  Unwind

  Scale-in to ~5% requires two consecutive quarters of >=6% cc growth with core margin >=40%. Kill criteria: core margin below 35%, group revenue turning negative as the 2027-28 Cosentyx/Kisqali cliff lands with no pipeline replacement, or a value-destroying large acquisition breaking the Narasimhan allocation record. Pluvicto plateauing is NOT an unwind — it is under 2% of revenue and is not the th

  Catalyst

  Q3 results late October 2026 — Kisqali and Scemblix growth rates, core margin trajectory, and buyback pace against the 2027-28 LOE guidance.

  Scenarios · 12mo targets

  $185.00 base

  $215.00 bull — Kisqali and Scemblix keep compounding double digits, core margin holds ~40%, and the pharma sector de-rates off IRA fear — a 14x franchise re-rates toward sector average.

  $130.00 bear — The 2027-28 Cosentyx/Kisqali cliff arrives with a thin bridge, Pluvicto plateaus near $2-3B against Lantheus/Telix competition, and NVS compounds at high single digits at a 12x multiple.

• BEAMBeam Therapeutics Inc. Common Stockbiology

  open1.23%+1.50pp43
  flow steadyconf

  Funder

  Origin platform for base editing (David Liu science, Broad-licensed): single-base correction without double-strand breaks — the most differentiated editing chemistry in the field — with ~$1.2B cash funding BEAM-302 in AATD into 2028, so it is not a hostage to a 2.35% real yield this year. Named flow: Eli Lilly's ~$1.3B acquisition of Verve in 2025 repriced in-vivo LNP editing as a strategic pharma

  Unwind

  Kill immediately on any grade 3+ hepatotoxicity or off-target signal in BEAM-302/301 (the Verve-101 precedent), on a discounted equity raise before AATD pivotal data, or if management redirects capital back to ex-vivo BEAM-101, whose Casgevy/bluebird unit economics are demonstrably broken and are not part of this thesis. Scale-in to the 3% sleeve cap only on clean multi-cohort BEAM-302 total-AAT a

  Catalyst

  BEAM-302 AATD Phase 1/2 dose-escalation update expected H2 2026 — total functional AAT levels and liver safety; BEAM-301 GSD1a first-in-human data.

  Scenarios · 12mo targets

  $42.00 base

  $75.00 bull — BEAM-302 shows durable correction with clean LFTs across cohorts; in-vivo base editing is validated as a modality and a large-pharma partnership or bid arrives as it did for Verve.

  $10.00 bear — A grade 3+ hepatotoxicity or off-target signal halts the in-vivo program, forcing a discounted raise; the platform permanently re-rates and ex-vivo economics offer no floor.

Warnings

• §2 cap re-applied after pillar tilt: KTOS
• §5.4 dry-powder: cash_pct 21.1% above base band top 15% allowed by §3b unfilled-sleeve headroom (+17.5pp, eff top 32.5%)
• cash_band: final cash 21.11% above neutral base band top 15% (escalator active: extension; §3b dry-powder headroom +17.5pp (unfilled opportunistic sleeve → cash)) (§5.4)

Conviction-lock actions

No conviction-lock refusals or overrides this run.

Cost breakdown

Per-call cost computed from cost.js pricing constants (Opus 4.7, Sonnet 4.6, Haiku 4.5). Cache-read tokens billed at 10% of input. See Cost & ROI for the rolling 30-day ledger.